Quarterly ResultAug 5, 2026, 04:04 PM
MannKind Q2 Revenue +43% to $109.4M; Afrezza, Furoscix FDA Approvals
AI Summary
MannKind reported a significant increase in total revenues for the second quarter of 2026, reaching $109.4 million, up 43% year-over-year. The company achieved three major catalysts, including FDA approvals for the pediatric indication of Afrezza and the Furoscix ReadyFlow autoinjector, alongside positive Phase 1b data for nintedanib DPI. Despite a net loss of $(19.0) million, these milestones are expected to fuel near-term growth and validate the company's diversification strategy.
Key Highlights
- Q2 2026 total revenues increased 43% year-over-year to $109.4 million.
- Afrezza pediatric indication received FDA approval on May 29, 2026.
- Furoscix ReadyFlow autoinjector received FDA approval on July 23, 2026.
- Furoscix generated $22.2 million in net sales for Q2 2026.
- Afrezza generated $17.0 million in net sales for Q2 2026.
- Cash, cash equivalents, and investments totaled $111 million as of June 30, 2026.
- Closed a $50 million private placement on July 24, 2026.
- Q2 2026 net loss was $(19.0) million, or $(0.06) per share.
Price Impact
More from MNKD